NASDAQ: PRTGPortage Biotech Inc Stock
$0.24-0.01 (-4%)
Updated Apr 25, 2024
PRTG Price
$0.24
Fair Value Price
$0.65
Market Cap
$4.69M
52 Week Low
$0.20
52 Week High
$4.40
P/E
-0.03x
P/B
0.15x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$144.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.55
Operating Cash Flow
-$16M
Beta
1.08
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PRTG Overview
Portage Biotech Inc. is a clinical-stage immuno-oncology company developing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The company's portfolio consists of five platforms leveraging delivery by (1) intratumorals, (2) nanoparticles, (3) liposomes, (4) aptamers, and (5) virus-like particles. Within these five platforms, the Company has 10 products under development. Portage Biotech was founded in 1973 and is headquartered in Tortola, British Virgin Islands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRTG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRTG ($0.24) is undervalued by 63.77% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PRTG ($0.24) is significantly undervalued by 63.77% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PRTG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRTG due diligence checks available for Premium users.
Be the first to know about important PRTG news, forecast changes, insider trades & much more!
PRTG News
Valuation
PRTG fair value
Fair Value of PRTG stock based on Discounted Cash Flow (DCF)
Price
$0.24
Fair Value
$0.65
Undervalued by
63.31%
PRTG ($0.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRTG ($0.24) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRTG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRTG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
15.41x
Market
40.97x
PRTG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.15x
Industry
5.8x
PRTG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRTG's financial health
Profit margin
Revenue
$0.0
Net Income
-$39.4M
Profit Margin
0%
PRTG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$49.0M
Liabilities
$17.7M
Debt to equity
0.55
PRTG's short-term assets ($7.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRTG's long-term liabilities ($15.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRTG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$5.3M
PRTG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRTG vs Biotech Stocks
Portage Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.